Survivorship in immune therapy: Assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center

Cancer Immunology Research

Volumn 3, Issue 5, 2015, Pages 464-469

  Johnson, Douglas B ^a   Friedman, Debra L ^a   Berry, Elizabeth ^a   Decker, Ilka ^a   Ye, Fei ^a   Zhao, Shilin ^a   Morgans, Alicia K ^a   Puzanov, Igor ^a   Sosman, Jeffrey A ^a   Lovly, Christine M ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIBODY; ANTIHISTAMINIC AGENT; BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; HYDROCORTISONE; INTERLEUKIN 2; IPILIMUMAB; METHYLPREDNISOLONE; NARCOTIC AGENT; PREDNISONE; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; TESTOSTERONE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE APPENDICITIS; ADRENAL INSUFFICIENCY; ADULT; AGED; AMNESIA; ANDROGEN THERAPY; APHASIA; ARM INJURY; ARTICLE; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVOR; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; COHORT ANALYSIS; COLITIS; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRY SKIN; ECZEMA; ENDOCRINE DISEASE; EPISCLERITIS; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GASTROINTESTINAL TOXICITY; HEALTH STATUS; HEMATOLOGIC DISEASE; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSITIS; HYPOPITUITARISM; IMMUNOTOXICITY; LACUNAR STROKE; LIMB WEAKNESS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTATIC MELANOMA; MORBIDITY; MORTALITY; MUSCLE DENERVATION; NEUROLOGICAL COMPLICATION; NEUROPATHIC PAIN; OVERALL SURVIVAL; PARESTHESIA; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; PRURITUS; RADIATION NECROSIS; RASH; RETROSPECTIVE STUDY; RIB FRACTURE; SEIZURE; SIDE EFFECT; SKIN DISEASE; SKIN GRAFT ULCER; SPINE FRACTURE; THYROID GLAND; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; UVEITIS; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HYPOPHYSIS DISEASE; IMMUNOTHERAPY; MELANOMA; NEURALGIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLITIS; DIARRHEA; DISEASE-FREE SURVIVAL; EXANTHEMA; HUMANS; IMMUNOTHERAPY; MELANOMA; NEURALGIA; PITUITARY DISEASES; PRURITUS; TREATMENT OUTCOME;

EID: 84962286789     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0217     Document Type: Article

References (29)

1. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. Highdose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16.
2. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994;271:907-13.
3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survivalwith ipilimumabinpatients with metastatic melanoma. N Engl J Med 2010;363:711-23.
4. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012;18: 2039-47.
5. McDermott D, Haanen J, Chen TT, Lorigan P, O'Day SInvestigators MDX. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol 2013;24:2694-8.
6. McDermott D, Lebbe C, Hodi FS, Maio M, Weber JS, Wolchok JD, et al. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev 2014;40:1056-64.
7. Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
8. Weber JS, Kahler KC, Hauschild A. Managementofimmune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30: 2691-7.
9. Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol 2011;22:991-3.
10. Delyon J, Mateus C, Lambert T. Hemophilia A induced by ipilimumab. N Engl J Med 2011;365:1747-8.
11. Johnson DB, Saranga-Perry V, Lavin PJ, Burnette WB, Clark SW, Uskavitch DR, et al. Myasthenia gravis induced by ipilimumab in metastatic melanoma patients. J Clin Oncol 2014 Apr 28. [Epub ahead of print]
12. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24: 2283-9.
13. Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 2014;99:4078-85.
14. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
15. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44.
16. Hamid O, Sosman JA, Lawrence DP, Sullivan RJ, Ibrahim N, Kluger HM, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma. J Clin Oncol 2013;31:9010.
17. Lovly CM, Dahlman KB, Fohn LE, Su Z, Dias-Santagata D, Hicks DJ, et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One 2012;7:e35309.
18. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012;366:207-15.
19. Callahan MK, Rampal R, Harding JJ, Klimek VM, Chung YR, Merghoub T, et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 2012;367:2316-21.
20. Keefe DL Trastuzumab-associated cardiotoxicity. Cancer 2002;95:1592-600.
21. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010;10:337.
22. Kantarjian HM, Keating MJ, Walters RS, Smith TL, Cork A, McCredie KB, et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol 1986;4:1748-57.
23. Nguyen PL, Alibhai SM, Basaria S, D'Amico AV, Kantoff PW, Keating NL, et al. Adverse effects of and rogen deprivation therapy and strategies to mitigate them. Eur Urol 2014 Aug 2. pii: S0302-2838(14)00650-2. [Epub ahead of print].
24. Gabriel SE Heart disease and rheumatoid arthritis: understanding the risks. Ann Rheum Dis 2010;69 Suppl 1:i61-4.
25. Bhushan V, Collins RH Jr Chronic graft-vs-host disease. JAMA 2003;290: 2599-603.
26. Strissel KJ, Denis GV, Nikolajczyk BS. Immune regulators of inflammation in obesity-associated type 2 diabetes and coronary artery disease. Curr Opin Endocrinol Diabetes Obes 2014;21:330-8.
27. + T-cell subsets and cardiovascular disease. J Intern Med 2013;274:41-51.
28. + T cells in blood from patients with coronary artery disease. Atherosclerosis 2012; 224:515-20.
29. Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014;21:371-81.